News | April 28, 2008

New-Generation CRT-D Device Implanted

April 29, 2008 - Sorin Group Cardiac Rhythm Management completed the first implant in a clinical trial of its new-generation PARADYM 8770 sonR cardiac resynchronization therapy defibrillator (CRT-D), introducing a technology based on hemodynamic response for continuous adjustment of cardiac resynchronization.

This system contains a technology named sonR designed to adjust CRT delivery based on hemodynamic response as opposed to conventional CRT-D devices, that monitor the electrical activity of the heart. PARADYM sonR is the first device delivering continuous management of resynchronization therapy during patients' everyday life.

What is unique about the defibrillator, according to the manufacturer, is that while conventional devices look at the heart as a clock, new PARADYM sonR looks at the heart as a pump, measuring vibrations generated by heart contraction. Thanks to this innovative approach, we provide the medical community and their patients with a completely new system, and this is in line with our vision to become an innovative leader in hemodynamic management of heart failure.

The new device with its son functionality is designed to measure and evaluate the performance of the cardiac pump, and to adapt the CRT settings to the patients' cardiac status automatically and recurrently during patients' everyday life.

A multi-centre clinical trial including 150 patients is currently being conducted across Europe. The first sonR systems, the PARADYM son CRT-D, including the sonR FIX atrial lead, were implanted by Professor Angelo Auricchio from Cardiocentro Ticino in Lugano, Switzerland, Peter Paul Delnoy, M.D., from Isala Clinics in Zwolle, Netherlands, and Neil Sulke, M.D., from Eastbourne General Hospital in the United Kingdom.

The PARADYM family also includes a single-chamber (VR 8250), and a dual-chamber (DR 8550) implantable cardioverter defibrillator for the management of arrhythmias.

For more information: www.soringroup-usa.com

Related Content

CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Overlay Init